How Should HIV Vaccine Efficacy Trials Be Conducted? Diverse U.S. Communities Speak Out

Autor/inn/en	Kegeles, Susan M.; Johnson, Mallory O.; Strauss, Ronald P.; Ralston, Brady; Hays, Robert B.; Metzger, David S.; McLellan-Lemal, Eleanor; MacQueen, Kathleen M.
Titel	How Should HIV Vaccine Efficacy Trials Be Conducted? Diverse U.S. Communities Speak Out
Quelle	In: AIDS Education and Prevention, 18 (2006) 6, S.560-572 (13 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0899-9546
DOI	10.1521/aeap.2006.18.6.560
Schlagwörter	Community Education; Immunization Programs; Community Involvement; Biomedicine; Medical Research; Communicable Diseases; Acquired Immunodeficiency Syndrome (AIDS); Prevention; Public Health; Interviews; Homosexuality; Drug Abuse; African Americans; At Risk Persons; Disclosure; Sampling; Trust (Psychology); Research Methodology; Cooperative Planning + Suchen Sie Ihr Suchwort? ; Gemeinschaftserziehung; Nachbarschaftserziehung; Immunisierung; Biomedizin; Contagious disease; Contagious diseases; Communicable disease; Infektionskrankheit; Prävention; Vorbeugung; Gesundheitswesen; Interviewing; Interviewtechnik; Homosexualität; Afroamerikaner; Risikogruppe; Research method; Forschungsmethode
Abstract	Developing an effective vaccine remains a critical long-term approach to HIV prevention. Every efficacy trial should be responsive to the concerns of participating communities because the successful development of an HIV preventive vaccine will require long-term involvement of people who have been marginalized and who distrust the government and biomedical research. Using qualitative interviews and purposive sampling, we elicited recommendations regarding how vaccine efficacy trials should be conducted from 90 members of communities that have been disproportionately affected by HIV/AIDS: injection drug users, gay men, and African Americans. The most common recommendation was for complete disclosure of all aspects of the trial. Other themes included participant and community education, who to include in trials, preventing harm, trust, community involvement, researcher attributes, and respect for participants. Developing positive, respectful and collaborative experiences with community members will facilitate vaccine research because negative experiences and unfavorable community reactions can greatly impede success in future trials. (As Provided).
Anmerkungen	Guilford Press. 72 Spring Street, New York, NY 10012. Tel: 800-365-7006; Tel: 212-431-9800; Fax: 212-966-6708; e-mail: info@guilford.com; Web site: http://www.guilford.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10